Polypharmacy and drug interactions amongst cirrhotic patients discharged from a tertiary center: Results from a national quality improvement audit
المؤلف | Abdel-Naser, Elzouki |
المؤلف | Zahid, Muhammad |
المؤلف | Akbar, Raza A. |
المؤلف | Alfitori, Gamal B. |
المؤلف | Cherichi Purayil, Saleema |
المؤلف | Imanullah, Rizwan |
المؤلف | Danjuma, Mohammed I. |
تاريخ الإتاحة | 2024-02-14T11:15:11Z |
تاريخ النشر | 2020-09-23 |
اسم المنشور | Arab Journal of Gastroenterology |
المعرّف | http://dx.doi.org/10.1016/j.ajg.2020.09.008 |
الاقتباس | Elzouki, A. N., Zahid, M., Akbar, R. A., Alfitori, G. B., Purayil, S. C., Imanullah, R., & Danjuma, M. I. (2020). Polypharmacy and drug interactions amongst cirrhotic patients discharged from a tertiary center: results from a national quality improvement audit. Arab Journal of Gastroenterology, 21(4), 216-218. |
الرقم المعياري الدولي للكتاب | 1687-1979 |
الملخص | Background and Study AimsAuditing of polypharmacy is particularly essential in patients with cirrhosis because of the crucial role of liver in drug metabolism. The aim of this study was to audit the drug prescribed in this group of patients and analyzed the quantity and severity of potential drug-drug interaction. Patients and MethodsIn this cross-sectional study we analyzed the last prescription as recorded in the Electronic Medical Record at the time of discharge for cirrhotic patients who were hospitalized during 24-months study period. Data were also collected for age, gender, and diagnoses. The drugs were analyzed for cross interactions using the Lexicomp-online e-formulary. The drug interactions are classified as: class A: no known interaction, class B: no action needed, Class C: monitor therapy, class D: consider therapy modification, and Class X: the drug should be avoided. ResultsA total of 333 patients with cirrhosis were audited, whereas complete and relevant data were available for 181 patients (134 males, 74%) with a mean age ± SD 59.7 ± 10.1. Out of these, 168 (92.8%) patients were using at least one medicine and the total number of medications used was 808 drugs. The observed average of utilization was 7.8 ± 3.1 drugs (range = 1–17) and 102 (56.3%) patients used polypharmacy. A total of 198 (24.5%) consumed drugs were related to cirrhosis and its complications. Six (3.3%), 30 (16.6%) and 65 (35.9%) patients had Class-X, Class D, and Class C, respectively. Utilization of polypharmacy was statistical significant in patients with class X (83.3%, p = 0.03), class D (16.6%, p = 0.01), and class C (35.9%, p = 0.02). ConclusionThe findings highlight the importance of auditing for polypharmacy to recognize and prevent potential drug-related problems in patients with cirrhosis. Implementation of strategies to optimize medication use in patients with cirrhosis should be considered necessary as it can have a bearing on length of stay and morbidity. |
اللغة | en |
الناشر | Elsevier |
الموضوع | Polypharmacy Cirrhosis Advanced liver disease Drug-drug interaction |
النوع | Article |
الصفحات | 216-218 |
رقم العدد | 4 |
رقم المجلد | 21 |
ESSN | 2090-2387 |
تحقق من خيارات الوصول
الملفات في هذه التسجيلة
هذه التسجيلة تظهر في المجموعات التالية
-
أبحاث الطب [1418 items ]